Floatz logo

Idov-Safetm

Advanced Malignant Solid Tumor of Digestive System

Peking UniversityEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Advanced Malignant Solid Tumor of Digestive System cohort.

Asset / SponsorPhaseRating
Toripalimab
Peking University
Early Phase 1C
Fruquintinib
Peking University
Early Phase 1C

Same molecule, other indications

Idov-Safetm is also rated in:

cancerDormant
CC
Indicative ·
45 / 100
View asset →
metastatic malignant neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
Advanced Solid TumorsDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →